Effectiveness of oseltamivir in the prevention and treatment of influenza in children

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Oseltamivir is an inhibitor of influenza virus neuraminidase and suppresses the reproduction of pathogen subtypes A and B. The drug contributes to reduction of the duration of influenza symptoms (febrile, headache, cough), and also reduces the incidence of complications (otitis media, etc.) in children aged 0–18 years. The effectiveness of oseltamivir has not been confirmed in influenza against the background of bronchial asthma and/or the drug is prescribed later than 48 hours from the onset of the disease. The drug is an independent means of chemoprophylaxis of influenza in persons who have been in contact with infected people.

Palavras-chave

Sobre autores

Eleonora Belan

Volgograd State Medical University, Department of Immunology and Allergology

Autor responsável pela correspondência
Email: belan.eleonora@yandex.ru
ORCID ID: 0000-0003-2674-4289

Dr. Sci. (Med.), Professor, Head of the Department of Immunology and Allergology

Rússia, Volgograd

E. Nikiforova

Volgograd State Medical University, Department of Immunology and Allergology

Email: belan.eleonora@yandex.ru
Rússia, Volgograd

Bibliografia

  1. Кардаш О.Ф. Осельтамивир: применение при гриппе. Рецепт. 2020;23(1):116–20. [Kardash O.F. Oseltamivir: use in influenza. Retsept. 2020;23(1):116–20. (In Russ.)]. doi: 10.34883/PI.2020.23.1.012.
  2. Методические рекомендации «Грипп и другие ОРВИ в период продолжающейся пандемии COVID-19: профилактика и лечение» (утв. Федеральным медико-биологическим агентством 10 ноября 2022 г.) [Guidelines “Influenza and other acute respiratory viral infections during the ongoing COVID-19 pandemic: prevention and treatment” (approved by the Federal Medical and Biological Agency on November 10, 2022). (In Russ.)].
  3. Касымова Е.Б., Башкина О.А., Галимзянов Х.М. и др. Оптимизация фармакотерапии у детей с острой Эпштейна–Барр вирусной инфекцией. Экспериментальная и клиническая фармакология. 2014;77(1):26–9. [Kasymova E.B., Bashkina O.A., Galimzyanov KH.M., et al. Optimization of pharmacotherapy in children with acute Epstein-Barr virus infection. Ehksperimental’naya i klinicheskaya farmakologiya. 2014;77(1):26–9. (In Russ.)].
  4. Li G., Yue T., Zhang P., et al. Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. Molecul. 2021;26(4):923. doi: 10.3390/molecules26040923.
  5. Stiver G. The treatment of influenza with antiviral drugs. CMAJ. 2003;168(1):49–56.
  6. Петров В.И., Белан Э.Б. Противовирусные средства. М., 2012. 224 с. [Petrov V.I., Belan E.B. Antivirals. M., 2012. 224 р. (In Russ.)].
  7. Collins P.J., Haire L.F., Lin Y.P., et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature. 2008;453(7199):1258–61. doi: 10.1038/nature06956.
  8. Hanpaibool C., Leelawiwat M., Takahashi K., Rungrotmongkol T. Source of oseltamivir resistance due to single E119D and double E119D/H274Y mutations in pdm09H1N1 influenza neuraminidase. J Comput Aided Mol Des. 2020;34(1):27–37. doi: 10.1007/s10822-019-00251-7.
  9. Macesic N., Laplante J.M., Aaron J.G., et al. Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients. Transpl Infect Dis. 2021;23(3):e13542. doi: 10.1111/tid.13542.
  10. McKimm-Breschkin J., Trivedi T., Hampson A., et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47(7):2264–72. doi: 10.1128/AAC.47.7.2264-2272.2003.
  11. Kiso M., Mitamura K., Sakai-Tagawa Y., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364(9436):759–65. doi: 10.1016/S0140-6736(04)16934-1. [PMID: 15337401].
  12. Tappenden P., Jackson R., Cooper K., et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess. 2009;13(11):iii, ix–xii, 1–246. doi: 10.3310/hta13110.
  13. Глебова Т.И., Кливлеева Н.Г., Лукманова Г.В. и др. Чувствительность к противовирусным препаратам штаммов вируса гриппа, выделенных в различных регионах Казахстана в 2018–2019 гг. Инфекция и иммунитет. 2021;11(6):1159–66. [Glebova T.I., Klivleyeva N.G., Lukmanova G.V., et al. 2018–2019 antiviral drug sensitivity of the influenza virus strains isolated from various regions of Kazakhstan. Infektsiya i immunitet=Rus J Infect Immun. 2021;11(6):1159–66. doi: 10.15789/2220-7619-ADS-1497. (In Russ.)].
  14. Осельтамивир. Официальная инструкция, зарегистрированная Минздравом РФ. [Oseltamivir. Official instructions registered by the Ministry of Health of the Russian Federation.https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=%d0%9b%d0%9f-005210&MnnR=&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1. (In Russ.)].
  15. Whitley R.J., Hayden F.G., Reisinger K.S., et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001 Feb;20(2):127-33. doi: 10.1097/00006454-200102000-00002. Erratum in: Pediatr Infect Dis J. 2001;20(4):421.
  16. Jefferson T., Jones M., Doshi P., et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545. doi: 10.1136/bmj.g2545.
  17. Lee J.J., Smith M., Bankhead C., et al. Oseltamivir and influenza-related complications in children: a retrospective cohort in primary care. Eur Respir J. 2020;56(5):1902246. doi: 10.1183/13993003.02246-2019.
  18. Malosh R.E., Martin E.T., Heikkinen T., et al. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2018;66(10):1492–500. doi: 10.1093/cid/cix1040.
  19. Qin J., Lin J., Zhang X., et al. Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children. Front Pharmacol. 2022;13:849545. doi: 10.3389/fphar.2022.849545.
  20. Mitamura K., Sugaya N., Nirasawa M., et al. [Effectiveness of oseltamivir treatment against influenza type A and type B infection in children]. Kansenshogaku Zasshi. 2002;76(11):946–52. Japanese. doi: 10.11150/kansenshogakuzasshi1970.76.946.
  21. Mattila J.M., Vuorinen T., Waris M., et al. Oseltamivir treatment of influenza A and B infections in infants. Influenza Other Respir Virus. 2021;15(5):618–24. doi: 10.1111/irv.12862.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2. Fig. 1

Baixar (435KB)
Metadados
3. Fig. 2

Baixar (301KB)
Metadados
4. Fig. 3

Baixar (477KB)
Metadados
5. Fig. 4

Baixar (337KB)
Metadados

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies